ARTICLE | Company News
EC approves Actelion's Uptravi
May 18, 2016 12:31 AM UTC
The European Commission approved Uptravi selexipag from Actelion Ltd. (SIX:ATLN) to treat pulmonary arterial hypertension (PAH). Actelion has rights to the long-acting prostacyclin (IP) receptor ( PGI...